Prolocor biomarker links high pFCG to repeat heart attacks in 765-patient study
Two peer-reviewed analyses of the same prospective trial tie elevated platelet FcγRIIa to a more than doubled risk of recurrent ischemic events without a matching rise in bleeding.
Executive Summary
- A completed, non-interventional multicenter trial found that a platelet biomarker separates myocardial infarction patients who go on to have repeat ischemic events from those who do not, with a large and statistically decisive effect.
- Because the trial only measured and tracked patients rather than assigning treatment based on the biomarker, the result establishes an association with risk, not that acting on the biomarker changes outcomes.
- The biomarker's signal tracked recurrent ischemic events without a matching rise in bleeding risk, a separation that matters because most tools for intensifying antiplatelet therapy carry a bleeding tradeoff.
- The company and outside investigators both frame the next step as a prospective trial that uses the biomarker to guide treatment, the design that would determine whether the association translates into a clinical decision tool.
The publication
Prolocor, Inc. announced on July 20, 2026 the publication of two analyses drawn from its completed, prospective multicenter trial (NCT05175261), one in JACC: Advances and one in Catheterization and Cardiovascular Interventions. Both papers use the same underlying dataset to argue that quantifying platelet FcγRIIa (pFCG) sharpens risk assessment after myocardial infarction. The trial enrolled 765 patients hospitalized with type 1 MI, each carrying at least two established risk factors such as age 65 or older, multivessel coronary disease, prior MI, chronic kidney disease, or diabetes, and followed them for an average of 21 months. NCT05175261+1NCT05175261Prolocor Announces the Publication of Two Important New Analyses from a Recently Completed Clinical StudyJul 20, 2026
The design
NCT05175261 is registered as a prospective, non-interventional observational study, meaning investigators measured pFCG levels and tracked outcomes without assigning treatment based on the result. The registered primary outcome compared the hazard ratio for a first occurrence of MI, stroke, or death between patients with high versus low pFCG, tracked over a study duration of up to three years. A secondary outcome compared hazard ratios for bleeding events graded BARC 2, 3, and 5 between the same high- and low-pFCG groups. That design licenses an associative claim about risk, not a causal claim about what happens if a clinician acts on the result. NCT05175261
The result
Patients with high pFCG carried a hazard ratio of 2.70 for ischemic events, meaning myocardial infarction, stroke, and death, with a 95% confidence interval of 1.82 to 4.02 and P < 0.0001. Investigators tracked 158 ischemic events and 74 clinically significant bleeding events across the cohort, and among the 47 patients who had two or more ischemic events, the repeat events spread across the full follow-up period rather than clustering near the index heart attack. High pFCG showed no statistically significant association with bleeding alone, with a hazard ratio of 1.39 and a 95% confidence interval of 0.63 to 3.06, P = 0.412. ProlocorProlocor Announces the Publication of Two Important New Analyses from a Recently Completed Clinical StudyJul 20, 2026
The separation
The result that stands out is the divergence between the ischemic and bleeding hazard ratios: a biomarker tied to a more than 2.5-times risk of repeat ischemic events showed no statistically meaningful tie to bleeding on its own. David Schneider, Prolocor's co-founder and chief scientific officer and the study's lead author, said the data show the test "does more than flag who is at risk after a heart attack, it identifies the patients most likely to suffer repeated ischemic events". C. Michael Gibson of the Baim Institute for Clinical Research and Harvard Medical School called it a signal that "could sharpen how we tailor antithrombotic therapy," while noting the results "warrant testing in a prospective, treatment-guiding trial". ProlocorProlocor Announces the Publication of Two Important New Analyses from a Recently Completed Clinical StudyJul 20, 2026
What comes next
Prolocor said it is focused on generating the evidence needed to commercialize the pFCG test, and both papers point to the same next step: a prospective trial that uses pFCG to guide treatment decisions rather than only to stratify risk after the fact. No timing for such a trial has been specified. Until that trial runs, the current result functions as a risk-stratification finding rather than evidence that changing therapy based on pFCG improves outcomes. ProlocorProlocor Announces the Publication of Two Important New Analyses from a Recently Completed Clinical StudyJul 20, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.